Treatment of aggressive non-hodgkin's lymphoma with dose-intensified epirubicin in combination of cyclophosphamide, vincristine, and prednisone (CEOP-100): A phase II study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 24, Issue 6, 2001, Pages 570-575

  Basaran, Mert ^a,c   Bavbek, E Sevil ^a   Sakar, Burak ^a   Eralp, Yesim ^a   Alici, Süleyman ^a   Tas, Faruk ^a   Yaman, Fulya ^a   Dogan, Öner ^b   Camlica, Hakan ^a   Onat, Haluk ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

CEOP; Epirubicin; Non Hodgkin's lymphoma; Phase II study; Treatment

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOTOXICITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISOLONE; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 0035209156     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200112000-00008     Document Type: Article

References (26)

1. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
2. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomized trial
3. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: Analysis of the completed trial and comparison with M-BACOD regimen
4. Comparison of a second-generation combination chemotherapeutic regimen (mBACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma
5. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma
6. An ECOG randomized phase III trial of CHOP vs. CHOP + radiotherapy (XRT) for intermediate grade early stage non-Hodgkin's lymphoma (NHL)
7. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma
8. Epirubicin cardiotoxicity. A study of 135 patients with advanced breast cancer
9. Cardiac morphology and functional changes induced by epirubicin chemotherapy
10. Cardiotoxicity of epirubicin and doxorubicin: Assessment by endomyocardial biopsy
11. Drugs ten years later: Epirubicin
12. Preliminary clinical experience with 4′-epi-doxorubicin in advanced human neoplasia
13. A revised European-American classification of lymphoid neoplasm: A proposal from the international lymphoma study group
14. Non-Hodgkin's lymphoma
15. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
16. Randomized phase II clinical trials
17. Dose escalation of CHOP in non-Hodgkin's lymphoma
18. Second cancers among long-term survivors of non-Hodgkin's lymphoma
19. Epirubicin in combination chemotherapy in the treatment of advanced stage non-Hodgkin's lymphomas
20. Dose escalation of epirubicin in the CEOP-bleo regimen: A controlled clinical trial comparing standard doses for the treatment of diffuse large cell lymphoma
21. Late effects in long term survivors of high grade non-Hodgkins lymphomas
22. A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin's lymphoma
23. CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma
24. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma
25. Chemotherapy of intermediate- and high grade non-Hodgkin's lymphomas with an intensive epirubicin-containing regimen
26. A predictive model for aggressive non-Hodgkin's lymphoma